Karyopharm Therapeutics (NASDAQ:KPTI) Downgraded by ValuEngine to “Hold”

ValuEngine cut shares of Karyopharm Therapeutics (NASDAQ:KPTI) from a buy rating to a hold rating in a report published on Thursday, ValuEngine reports.

KPTI has been the topic of several other research reports. Zacks Investment Research downgraded shares of ExlService from a hold rating to a sell rating in a report on Wednesday. HC Wainwright reiterated a buy rating and issued a $48.00 price target (down previously from $52.00) on shares of CELYAD SA/ADR in a report on Friday, July 5th. Wedbush set a $11.00 price target on shares of Sangamo Therapeutics and gave the stock a hold rating in a report on Monday. BidaskClub upgraded shares of Zumiez from a sell rating to a hold rating in a report on Saturday, June 22nd. Finally, Robert W. Baird reiterated an outperform rating and issued a $25.00 price target (up previously from $15.00) on shares of Karyopharm Therapeutics in a report on Friday, July 5th. One analyst has rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the company’s stock. The stock has an average rating of Buy and a consensus target price of $17.41.

NASDAQ:KPTI traded down $0.05 during midday trading on Thursday, hitting $7.56. The company’s stock had a trading volume of 59,044 shares, compared to its average volume of 4,435,388. Karyopharm Therapeutics has a fifty-two week low of $3.92 and a fifty-two week high of $21.71. The company’s 50 day simple moving average is $6.33. The company has a debt-to-equity ratio of 0.98, a quick ratio of 6.19 and a current ratio of 6.19. The company has a market capitalization of $454.02 million, a price-to-earnings ratio of -2.39 and a beta of 2.43.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($1.09) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.84) by ($0.25). Karyopharm Therapeutics had a negative return on equity of 119.66% and a negative net margin of 1,005.85%. The business had revenue of $0.16 million during the quarter, compared to analyst estimates of $0.75 million. On average, sell-side analysts anticipate that Karyopharm Therapeutics will post -3.68 earnings per share for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the business. Two Sigma Investments LP boosted its position in Karyopharm Therapeutics by 53.2% in the 4th quarter. Two Sigma Investments LP now owns 611,153 shares of the company’s stock worth $5,727,000 after purchasing an additional 212,196 shares in the last quarter. FMR LLC boosted its position in Karyopharm Therapeutics by 51.5% in the 4th quarter. FMR LLC now owns 1,875,140 shares of the company’s stock worth $17,570,000 after purchasing an additional 637,357 shares in the last quarter. Deutsche Bank AG boosted its position in Karyopharm Therapeutics by 79.1% in the 4th quarter. Deutsche Bank AG now owns 479,323 shares of the company’s stock worth $4,489,000 after purchasing an additional 211,764 shares in the last quarter. Premier Asset Management LLC purchased a new stake in Karyopharm Therapeutics in the 4th quarter worth approximately $282,000. Finally, First Midwest Bank Trust Division boosted its position in Karyopharm Therapeutics by 259.2% in the 1st quarter. First Midwest Bank Trust Division now owns 610,850 shares of the company’s stock worth $3,567,000 after purchasing an additional 440,769 shares in the last quarter. Institutional investors and hedge funds own 84.20% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase IIb clinical study in treatments of refractory multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for multiple myeloma patients; Phase III clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; Phase IIb clinical study in diffuse large B-cell lymphoma; Phase II/III clinical study in liposarcoma; Phase III clinical trial in endometrial cancer; and Phase II clinical trial in glioblastoma multiforme.

See Also: Resistance Level

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.